Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | CRHBP | P24387 | 1/20 | 0.31 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30492970 | 1.00 | NFE2L2 (0.42) | NFE2L2CRHBPCRHR2KDM4EALDH1A1 | |
| SCHEMBL30492967 | 1.00 | NFE2L2 (0.42) | NFE2L2CRHBPCRHR2KDM4EALDH1A1 | |
| SCHEMBL15940560 | 1.00 | NFE2L2 (0.42) | NFE2L2CRHBPCRHR2KDM4EALDH1A1 | |
| SCHEMBL20602058 | 0.85 | ALDH1A1 (0.32) | NFE2L2KDM4EALDH1A1MAPTHTT | |
| SCHEMBL15940699 | 0.85 | NFE2L2 (0.30) | NFE2L2KDM4EALDH1A1MAPTHTT | |
| SCHEMBL15940698 | 0.85 | NFE2L2 (0.30) | NFE2L2KDM4EALDH1A1MAPTHTT | |
| SCHEMBL845895 | 0.80 | NFE2L2 (0.48) | NFE2L2CRHBPCRHR2KDM4EALDH1A1 | |
| SCHEMBL845894 | 0.80 | NFE2L2 (0.48) | NFE2L2CRHBPCRHR2KDM4EALDH1A1 | |
| SCHEMBL20477221 | 0.76 | L3MBTL1 (0.37) | KDM4EALDH1A1MAPTKMT2A | |
| SCHEMBL20602580 | 0.75 | NFE2L2 (0.45) | NFE2L2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2953456-B1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C | MERCK SHARP & DOHME (US) | 2019-05-22 | — | — | EP | disclosed |
| US-9243002-B2 | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis C | MERCK SHARP & DOHME CORP. (US) | 2016-01-26 | — | — | US | disclosed |
| US-20150361101-A1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C | MERCK SHARP & DOHME CORP. (US) | 2015-12-17 | — | — | US | disclosed |
| EP-2953456-A1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C | Merck Sharp & Dohme Corp. (US) | 2015-12-16 | — | — | EP | disclosed |
| WO-2014121416-A1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C | MERCK SHARP & DOHME CORP. (US) | 2014-08-14 | — | — | WO | disclosed |
| WO-2014123793-A1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C | MERCK SHARP & DOHME CORP. (US) | 2014-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361101-A1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C | HCCS, HAVCR2, CYP7A1 | NFE2L2 843/4885CRHBP 3409/4885CRHR2 4283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.